The article "Targeting MYC at the intersection between cancer metabolism and oncoimmunology" by Simran Venkatraman et al. explores the role of MYC in cancer metabolism and oncoimmunology. MYC, a proto-oncogenic transcription factor, governs various cellular processes including cell proliferation, survival, and metabolism. The authors highlight how MYC interacts with its partners and cofactors to influence both oncometabolism and oncoimmunology. Key interactions with HIF-1α are noted, as they promote glucose and glutamine metabolism and antigen presentation on regulatory T cells. The review discusses the therapeutic potential of targeting MYC, including the development of Omomyc, a MAX-interfering peptide, which has shown promising results in preclinical models. The article also reviews the challenges and perspectives in developing MYC-targeted therapies, emphasizing the need for further research to overcome the "undruggable" nature of MYC. The authors conclude that targeting MYC could be a promising strategy to combat both metabolic reprogramming and immune evasion in cancer.The article "Targeting MYC at the intersection between cancer metabolism and oncoimmunology" by Simran Venkatraman et al. explores the role of MYC in cancer metabolism and oncoimmunology. MYC, a proto-oncogenic transcription factor, governs various cellular processes including cell proliferation, survival, and metabolism. The authors highlight how MYC interacts with its partners and cofactors to influence both oncometabolism and oncoimmunology. Key interactions with HIF-1α are noted, as they promote glucose and glutamine metabolism and antigen presentation on regulatory T cells. The review discusses the therapeutic potential of targeting MYC, including the development of Omomyc, a MAX-interfering peptide, which has shown promising results in preclinical models. The article also reviews the challenges and perspectives in developing MYC-targeted therapies, emphasizing the need for further research to overcome the "undruggable" nature of MYC. The authors conclude that targeting MYC could be a promising strategy to combat both metabolic reprogramming and immune evasion in cancer.